According to Technavio's analyst, the human vaccine market size is expected to be valued at USD 20.37 billion by 2026 at a progressing CAGR of 7.73%. One of the key highlights of the human vaccine market research report is the post COVID-19 impact analysis on the market, which will help companies evaluate their business approaches for the forecast period. The human vaccine market report offers information on several market vendors, including Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BioNTech SE, CanSino Biologics Inc., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Moderna Inc., Novavax Inc., Pfizer Inc., Sanofi, and Serum Institute of India Pvt. Ltd. among others. Furthermore, the human vaccine market has been broadly categorized into the following demographic segmentations:
- Route of administration - Intramuscular, subcutaneous, oral, and others
- Geography - North America, Europe, Asia, and Rest of World (ROW)
What will the Human Vaccine Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Human Vaccine Market Size for the Forecast Period and Other Important Statistics
Human Vaccine Market: Key Drivers, Trends, and Challenges
Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The increase in investments in the vaccines segment is notably driving the human vaccine market growth, although factors such as concerns about the safety of vaccines may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the human vaccine industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Human Vaccine Market Driver
- The increase in investments in the vaccines segment is one of the key drivers fueling the human vaccine market growth.
- Companies across the world are increasingly investing in new vaccine development.
- For instance, in November 2020, CEPI received a grant of up to $20 million from the Bill and Melinda Gates Foundation to expand its portfolio of COVID-19 vaccines to include candidates that are different from those already in the advanced development stage.
- In December 2020, China's Sinovac Biotech announced that it had secured approximately $500 million in funding for the development of its COVID-19 vaccine. In 2021, the United States International Development Finance Corporation (DFC) invested $2.3 billion in India for the development of vaccines.
Such increasing investments will drive the human vaccine market growth during the forecast period.
Key Human Vaccine Market Trend
- Varied demand for vaccines in high-income and developing countries is one of the key human vaccine market trends contributing to the market growth.
- The demand for novel vaccines is high in developing countries, which receive financial support. In addition, the willingness to pay for immunization may be less in countries without funding or proper reimbursements for vaccinations.
- Manufacturers in developing countries face challenges, such as high R&D costs and difficulty in conducting large placebo-controlled trials, where infection rates in vaccinated people may be compared with rates in the placebo-controlled group.
- Vaccine industry associations, such as the Developing Countries Vaccines Manufacturers Network (DCVMN), serve as platforms to encourage the development of novel vaccines. This, in turn, will drive the human vaccine market growth during the forecast period.
Key Human Vaccine Market Challenge
- Concerns about the safety of vaccines is one of the factors hindering the human vaccine market growth.
- Vaccination product leaflets may list a few side effects which may be noticed in the controlled group.
- For instance, the dengue vaccine has serious effects, including the occurrence of severe hemorrhagic dengue fever.
- The concerns about the safety of vaccines in young children are increasing because they are less likely to be exposed to dengue before getting the dengue vaccine.
- HPV vaccines have resulted in many safety issues, such as postural tachycardia syndrome and chronic fatigue syndrome. Thus, safety concerns about vaccines may hinder the growth of the global human vaccine market during the forecast period.
This human vaccine market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Parent Market Analysis
Technavio categorizes the global human vaccine market as a part of the global pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the human vaccine market during the forecast period.
Who are the Major Human Vaccine Market Vendors?
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bavarian Nordic AS
- Bharat Biotech Ltd.
- BioNTech SE
- CanSino Biologics Inc.
- CSL Ltd.
- Daiichi Sankyo Co. Ltd.
- Emergent BioSolutions Inc.
- GlaxoSmithKline Plc
- Gradalis Inc.
- Inovio Pharmaceuticals Inc.
- Johnson and Johnson
- Merck and Co. Inc.
- Mitsubishi Chemical Holdings Corp.
- Moderna Inc.
- Novavax Inc.
- Pfizer Inc.
- Sanofi
- Serum Institute of India Pvt. Ltd.
This statistical study of the human vaccine market encompasses successful business strategies deployed by the key vendors. The human vaccine market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
Product Insights and News
- Bavarian-nordic.com - The company offers ABNCoV2 which is a next-generation COVID-19 vaccine being developed as a universal booster to boost the immunity system among humans and to fight against variants of the SARS-CoV-2 virus.
- Csl.com - The company offers cell-based seasonal influenza vaccine and next-generation self-amplifying mRNA for generating immune responses inside the body to fight against a particular disease.
- Daiichisankyo.com - The company offers Human vaccine DS-5670 which is a mRNA developed in Japan have been evaluated against the novel coronavirus infectious disease.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The human vaccine market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Human Vaccine Market Value Chain Analysis
Our report provides extensive information on the value chain analysis for the human vaccine market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
Which are the Key Regions for Human Vaccine Market?

For more insights on the market share of various regions Request for a FREE sample now!
38% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the human vaccine market in North America. Market growth in this region will be faster than the growth of the market in ROW.
The increasing number of immunization programs and strong prevalence of infectious diseases will facilitate the human vaccine market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The outbreak of COVID-19 had a positive impact on the regional market. However, by 2023, it is expected that a large proportion of the population will be vaccinated against COVID-19 in North America. Therefore, the market growth of the COVID-19 vaccine might decline in the region during the forecast period.
What are the Revenue-generating Route of Administration Segments in the Human Vaccine Market?

To gain further insights on the market contribution of various segments Request for a FREE sample
The human vaccine market share growth by the intramuscular segment will be significant during the forecast period. The intramuscular segment is expected to witness accelerated growth during the forecast period. One of the main reasons for this growth is the benefits of intramuscular administration. It is efficient and safe in inducing an immune response compared with the oral ROA. Many pipeline vaccine products are being evaluated in the intramuscular ROA because of their advantages over the oral ROA. Thus, the market has witnessed the development and approval of an intramuscular vaccine for COVID-19, which is expected to drive the growth of the segment during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the human vaccine market size and actionable market insights on post COVID-19 impact on each segment.
Human Vaccine Market Scope
|
Report Coverage
|
Details
|
Page number
|
120
|
Base year
|
2021
|
Forecast period
|
2022-2026
|
Growth momentum & CAGR
|
Accelerate at a CAGR of 7.73%
|
Market growth 2022-2026
|
$ 20.37 billion
|
Market structure
|
Fragmented
|
YoY growth (%)
|
5.3
|
Regional analysis
|
North America, Europe, Asia, and Rest of World (ROW)
|
Performing market contribution
|
North America at 38%
|
Key consumer countries
|
US, Canada, Germany, UK, and China
|
Competitive landscape
|
Leading companies, Competitive strategies, Consumer engagement scope
|
Key companies profiled
|
Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BioNTech SE, CanSino Biologics Inc., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Moderna Inc., Novavax Inc., Pfizer Inc., Sanofi, and Serum Institute of India Pvt. Ltd.
|
Market dynamics
|
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
|
Customization purview
|
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
|
Request for a FREE sample
What are the Key Data Covered in this Human Vaccine Market Report?
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will drive human vaccine market growth during the next five years
- Precise estimation of the human vaccine market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the human vaccine industry across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of human vaccine market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch